Neovacs Acquires Interferon Alpha Manufacturing Technology From AMEGABIOTECH
November 15 2016 - 2:15AM
Neovacs (Alternext Paris:ALNEV)
,
a leader in active immunotherapies for the treatment of autoimmune
diseases, today announced an agreement with the Argentinean company
AMEGABIOTECH to acquire its Interferon Alpha
(IFNα) manufacturing license. IFNα is a key component of Neovacs’
lead therapeutic candidate, IFNα Kinoid, which is composed of
inactivated IFNα coupled with a carrier protein, keyhole limpet
hemocyanin.
Miguel Sieler, CEO of Neovacs,
commented: "With this agreement, the company has reinforced its
ability to maintain control of its technology, quality control,
manufacturing and costs, which is key to our overall growth
strategy as we continue advancing the clinical development of our
lead candidate IFNα Kinoid. With greater control over our
Kinoid technology, we can drive optimization of manufacturing costs
and more effectively support the potential commercialization of
IFNα Kinoid for the treatment of lupus, a complex autoimmune
disease where medical needs are urgent and unmet today.”
AMEGABIOTECH is a leading
global producer of IFNα protein and a long term supplier of
Neovacs, particularly for its on-going Phase IIb study of IFNα
Kinoid in Lupus. Their product is recognized by the international
biotechnology and pharmaceutical industry for the quality of its
technological manufacturing, which also meets all relevant
international standards for GMP (Good manufacturing Practice).
About AMEGABIOTECH
"AMEGABIOTECH is a- leader in development, production and
commercialization of biotech products for human health - located in
Argentina. Exporting recombinant proteins worldwide and focused on
central markets registrations, AMEGA Biotech is the leading
regional producer. Their work and vision are directed forward.
Their core operations are based on a comprehensive design and
integration of all the processes involved in the production of high
technology products, from cell engineering to APIproduction and
Finished Dosage Forms manufacturing. Their development and
production model is a competitive advantage in the regional and
world biotechnology industry, allowing us to face the future and
constant challenges of a dynamic field. AMEGABIOTECH contributes to
the future of biotechnology by understanding its high impact on
society and its benefits on human
health." http://www.amega-biotech.com.ar/
About Neovacs TechnologyNeovacs
targets pathologies associated with an overproduction of endogenous
cytokines. This technology is based on active immunotherapy to
generate an immune response through the administration of an
immunogenic complex involving the target cytokine to a carrier
protein. The intramuscular injection of this Kinoid induces an
immune response and stimulates the production of polyclonal
antibodies against the target cytokines. It is thus possible to
block cytokine overproduction and its pharmacological effects.
Several autoimmune and inflammatory diseases (Type 1 diabetes,
systemic lupus erythematosus, psoriasis, etc.) are characterized by
a disorder of cytokines that are found produced in excess (ex:
IFNa). This overproduction will promote inflammation and
dysregulation of the immune system.
About NeovacsListed on
Alternext Paris since 2010, Neovacs is today a leading
biotechnology company focused on an active immunotherapy technology
platform (Kinoids) with applications in autoimmune and/or
inflammatory diseases. On the basis of the company’s proprietary
technology for inducing a polyclonal immune response (covered by
five patent families that potentially run until 2032) Neovacs is
focusing its clinical development efforts on IFNα-Kinoid, an
immunotherapy being developed for the indication of lupus,
dermatomyositis and also in preclinical trial for Type 1 diabetes.
Neovacs is also conducting preclinical development works on other
therapeutic vaccines in the fields of auto-immune diseases,
oncology and allergies. The goal of the Kinoid approach is to
enable patients to have access to safe treatments with efficacy
that is sustained in these life-long diseases. www.neovacs.fr
Contacts
NEOVACS – Corporate Communication & Investor Relations
Charlène Masson
+33 (0)1 53 10 93 14
cmasson@neovacs.com
Investor Relations / Financial Communications Germany – MC Services
Raimund Gabriel
+49-89-21-02-28-30
raimund.gabriel@mc-services.eu
Press / U.S. Inquiries – The Ruth Group
Lee Roth / Joseph Green
+1-646-536-7012 / 7013
lroth@theruthgroup.com / jgreen@theruthgroup.com
Neovacs (EU:ALNEV)
Historical Stock Chart
From Sep 2024 to Oct 2024
Neovacs (EU:ALNEV)
Historical Stock Chart
From Oct 2023 to Oct 2024